• Something wrong with this record ?

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

P. Correale, RE. Saladino, D. Giannarelli, R. Giannicola, R. Agostino, N. Staropoli, A. Strangio, T. Del Giudice, V. Nardone, M. Altomonte, P. Pastina, P. Tini, AC. Falzea, N. Imbesi, V. Arcati, G. Romeo, D. Caracciolo, A. Luce, M. Caraglia, A....

. 2020 ; 8 (1) : . [pub] -

Language English Country Great Britain

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026692

Grant support
NV17-32285A MZ0 CEP Register

BACKGROUND: Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue human leukocyte antigen (HLA) molecules. Nivolumab is currently an active but expensive therapeutic agent for metastatic non-small cell lung cancer (mNSCLC), producing, in some cases, immune-related adverse events (irAEs). At the present, no reliable biomarkers have been validated to predict either treatment response or adverse events in treated patients. METHODS: We performed a retrospective multi-institutional analysis including 119 patients with mNSCLC who received PD-1 blockade since November 2015 to investigate the predictive role of germinal class I HLA and DRB1 genotype. We investigated the correlation among patients' outcome and irAEs frequency with specific HLA A, B, C and DRB1 alleles by reverse sequence-specific oligonucleotide (SSO) DNA typing. RESULTS: A poor outcome in patients negative for the expression of two most frequent HLA-A alleles was detected (HLA: HLA-A*01 and or A*02; progression-free survival (PFS): 7.5 (2.8 to 12.2) vs 15.9 (0 to 39.2) months, p=0.01). In particular, HLA-A*01-positive patients showed a prolonged PFS of 22.6 (10.2 to 35.0) and overall survival (OS) of 30.8 (7.7 to 53.9) months, respectively. We also reported that HLA-A and DRB1 locus heterozygosis (het) were correlated to a worse OS if we considered het in the locus A; in reverse, long survival was correlated to het in DRB1. CONCLUSIONS: This study demonstrate that class I and II HLA allele characterization to define tumor immunogenicity has relevant implications in predicting nivolumab efficacy in mNSCLC and provide the rationale for further prospective trials of cancer immunotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026692
003      
CZ-PrNML
005      
20211026132707.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jitc-2020-000733 $2 doi
035    __
$a (PubMed)32554614
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Correale, Pierpaolo $u Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy michele.caraglia@unicampania.it correalep@yahoo.com
245    10
$a Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade / $c P. Correale, RE. Saladino, D. Giannarelli, R. Giannicola, R. Agostino, N. Staropoli, A. Strangio, T. Del Giudice, V. Nardone, M. Altomonte, P. Pastina, P. Tini, AC. Falzea, N. Imbesi, V. Arcati, G. Romeo, D. Caracciolo, A. Luce, M. Caraglia, A. Giordano, L. Pirtoli, A. Necas, E. Amler, V. Barbieri, P. Tassone, P. Tagliaferri
520    9_
$a BACKGROUND: Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue human leukocyte antigen (HLA) molecules. Nivolumab is currently an active but expensive therapeutic agent for metastatic non-small cell lung cancer (mNSCLC), producing, in some cases, immune-related adverse events (irAEs). At the present, no reliable biomarkers have been validated to predict either treatment response or adverse events in treated patients. METHODS: We performed a retrospective multi-institutional analysis including 119 patients with mNSCLC who received PD-1 blockade since November 2015 to investigate the predictive role of germinal class I HLA and DRB1 genotype. We investigated the correlation among patients' outcome and irAEs frequency with specific HLA A, B, C and DRB1 alleles by reverse sequence-specific oligonucleotide (SSO) DNA typing. RESULTS: A poor outcome in patients negative for the expression of two most frequent HLA-A alleles was detected (HLA: HLA-A*01 and or A*02; progression-free survival (PFS): 7.5 (2.8 to 12.2) vs 15.9 (0 to 39.2) months, p=0.01). In particular, HLA-A*01-positive patients showed a prolonged PFS of 22.6 (10.2 to 35.0) and overall survival (OS) of 30.8 (7.7 to 53.9) months, respectively. We also reported that HLA-A and DRB1 locus heterozygosis (het) were correlated to a worse OS if we considered het in the locus A; in reverse, long survival was correlated to het in DRB1. CONCLUSIONS: This study demonstrate that class I and II HLA allele characterization to define tumor immunogenicity has relevant implications in predicting nivolumab efficacy in mNSCLC and provide the rationale for further prospective trials of cancer immunotherapy.
650    _2
$a senioři $7 D000368
650    _2
$a alely $7 D000483
650    _2
$a nemalobuněčný karcinom plic $x genetika $x mortalita $7 D002289
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zárodečné mutace $x genetika $7 D018095
650    _2
$a HLA antigeny $x metabolismus $7 D006680
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory kontrolních bodů $x farmakologie $x terapeutické užití $7 D000082082
650    _2
$a nádory plic $x genetika $x mortalita $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Saladino, Rita Emilena $u Tissue Typing Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Giannarelli, Diana $u Regina Elena National Cancer Institute, IRCCS, Rome, Italy
700    1_
$a Giannicola, Rocco $u Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Agostino, Rita $u Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Staropoli, Nicoletta $u Medical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
700    1_
$a Strangio, Alessandra $u Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Del Giudice, Teresa $u Medical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
700    1_
$a Nardone, Valerio $u Radiotherapy Unit, "Ospedale del Mare", ASL Napoli 1, Naples, Italy
700    1_
$a Altomonte, Maria $u Unit of Pharmacy, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Pastina, Pierpaolo $u Section of Radiation Oncology, Medical School, University of Siena, Siena, Italy
700    1_
$a Tini, Paolo $u Section of Radiation Oncology, Medical School, University of Siena, Siena, Italy
700    1_
$a Falzea, Antonia Consuelo $u Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Imbesi, Natale $u Tissue Typing Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Arcati, Valentina $u Tissue Typing Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Romeo, Giuseppa $u Tissue Typing Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
700    1_
$a Caracciolo, Daniele $u Medical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
700    1_
$a Luce, Amalia $u Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy
700    1_
$a Caraglia, Michele $u Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy michele.caraglia@unicampania.it correalep@yahoo.com $u Biogem Scarl, Institute of Genetic Research, Laboratory of Precision and Molecular Oncology, Ariano Irpino, Avellino, Italy
700    1_
$a Giordano, Antonio $u Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA $u Department of Medical Biotechnology, University of Siena, Siena, Italy
700    1_
$a Pirtoli, Luigi $u Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA
700    1_
$a Necas, Alois $u Central European Institute of Technology, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic
700    1_
$a Amler, Evzen $u Department of Biophysics, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Barbieri, Vito $u Medical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
700    1_
$a Tassone, Pierfrancesco $u Medical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy $u Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA
700    1_
$a Tagliaferri, Pierosandro $u Medical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
773    0_
$w MED00201262 $t Journal for immunotherapy of cancer $x 2051-1426 $g Roč. 8, č. 1 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32554614 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132714 $b ABA008
999    __
$a ok $b bmc $g 1715432 $s 1147199
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c 1 $e - $i 2051-1426 $m Journal for immunotherapy of cancer $n J Immunother Cancer $x MED00201262
GRA    __
$a NV17-32285A $p MZ0
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options